Compare ASTS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTS | VTRS |
|---|---|---|
| Founded | 2019 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5B | 18.7B |
| IPO Year | 2019 | 2019 |
| Metric | ASTS | VTRS |
|---|---|---|
| Price | $58.56 | $17.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $79.61 | $19.40 |
| AVG Volume (30 Days) | ★ 7.6M | 7.5M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.73% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $4,400,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $138.08 | $3.42 |
| Revenue Next Year | $275.59 | $1.68 |
| P/E Ratio | ★ N/A | $349.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $49.31 | $9.69 |
| 52 Week High | $133.86 | $18.43 |
| Indicator | ASTS | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 59.10 |
| Support Level | $54.78 | $15.94 |
| Resistance Level | $67.20 | $18.23 |
| Average True Range (ATR) | 3.20 | 0.45 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 22.46 | 65.61 |
AST SpaceMobile Inc is currently designing, developing and manufacturing the constellation of BlueBird (BB) satellites and has begun launching its planned space-based Cellular Broadband network distributed through a constellation of low Earth orbit (LEO) satellites. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.